Last reviewed · How we verify

NCT05617118: BvsB

BTA vs Baclofen for Pelvic Myofascial Pain Syndrome

Status unknown Last updated 11 April 2023
What this trial tests

trial testing Baclofen 10mg in Chronic Pain in 52 participants. Status unknown.

Timeline
1 December 2022
Primary endpoint
31 December 2023
1 May 2024

Quick facts

Lead sponsorSaint Petersburg State University, Russia
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment52
Start date1 December 2022
Primary completion31 December 2023
Estimated completion1 May 2024
Sites1 location across Russia

Drugs / interventions tested

Conditions studied

Sponsor

Saint Petersburg State University, Russia

Who can join

Adults 18 to 75, any sex, with Chronic Pain or Chronic Pelvic Pain Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to test the hypothesis that oral taking of baclofen in therapeutic dosage for 60 days is equally effective as injection of botulinum toxin type "A" in the area of trigger points of the pelvic muscles.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Baclofen 10mg

Trials testing the same drug.

Other recruiting trials for Chronic Pain

Currently open trials in the same condition.

Other Saint Petersburg State University, Russia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05617118.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing